GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Unlike conventional incretin-based drugs ... This unique approach sets it apart from existing therapies. Current GLP-1-based obesity medications are effective in achieving 15-20% weight loss ...

Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 programPivotal Phase 3 trials designed to leverage the ...

Hanmi Presents Three Breakthrough Findings on Novel Obesity Drugs at 2024 ObesityWeek High Quality Obesity Management by ...